Mepolizumab reduces asthma exacerbations among real-world patients with severe asthma and an eosinophilic phenotype.

Perspectives from John J. Oppenheimer, MD; Sarah Rhoads, MD Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was deemed ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...